智通财经APP获悉，和黄医药(00013)再涨超4%，月内累计涨幅超20%。截至发稿，涨3.68%，报24.8港元，成交额1.42亿港元。
消息面上，和黄医药宣布，SACHI III期研究的结果于《柳叶刀》发表。SACHI是一项赛沃替尼(savolitinib)和奥希替尼(osimertinib)的联合疗法，用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的III期研究。
据悉，赛沃替尼是一种强效、高选择性的口服MET TKI，由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。奥希替尼是一种不可逆的第三代EGFR TKI 。基于SACHI研究的数据，赛沃替尼和奥希替尼的联合疗法已于2025年6月在中国获批。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.